Most people with paroxysmal nocturnal hemoglobinuria (PNH) benefited from Soliris (eculizumab) therapy when they adhered to strict treatment guidelines, a real-world Dutch study showed. Because most had an incomplete response, new therapies are needed to improve real-world outcomes, however, the study’s researchers suggested, and emphasized that their data could…
News
Recent Posts
- New report highlights benefits of early detection and treatment in PNH
- Why I’m looking forward with hope for new therapies or even a cure
- Limited treatment access drives poor PNH outcomes in South India
- This year, I’m choosing strength, balance, and purpose
- Abnormal NK cells may disrupt immune activity in PNH: Study